EP0198003A1 - Cough-relieving compositions - Google Patents
Cough-relieving compositionsInfo
- Publication number
- EP0198003A1 EP0198003A1 EP85905100A EP85905100A EP0198003A1 EP 0198003 A1 EP0198003 A1 EP 0198003A1 EP 85905100 A EP85905100 A EP 85905100A EP 85905100 A EP85905100 A EP 85905100A EP 0198003 A1 EP0198003 A1 EP 0198003A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- carrier
- process according
- compositions
- fat
- hog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 206010011224 Cough Diseases 0.000 title claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 239000010642 eucalyptus oil Substances 0.000 claims abstract description 15
- 229940044949 eucalyptus oil Drugs 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 235000003351 Brassica cretica Nutrition 0.000 claims abstract description 12
- 235000003343 Brassica rupestris Nutrition 0.000 claims abstract description 12
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000010460 mustard Nutrition 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 244000056139 Brassica cretica Species 0.000 claims abstract 3
- 230000002195 synergetic effect Effects 0.000 claims abstract 3
- 239000011505 plaster Substances 0.000 claims description 14
- 239000000853 adhesive Substances 0.000 claims description 9
- 230000001070 adhesive effect Effects 0.000 claims description 9
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 7
- 229920000742 Cotton Polymers 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000004753 textile Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000009738 saturating Methods 0.000 claims description 2
- 230000001914 calming effect Effects 0.000 abstract 2
- 235000015277 pork Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 18
- 241000219198 Brassica Species 0.000 description 9
- 206010006451 bronchitis Diseases 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000011888 foil Substances 0.000 description 6
- 229920000915 polyvinyl chloride Polymers 0.000 description 6
- 239000004800 polyvinyl chloride Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- -1 thimol Substances 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011241 protective layer Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010011225 Cough decreased Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 206010056397 Tracheomalacia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical group C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
Definitions
- the present invention relates to physiologically calmative and sedative cough-relieving compositions and a method for relieving cough by the aid of the said compositions.
- Codein morphine monomethyl ether
- other galenic formulations e.g. anisated expectorant liquid, elixir comprising eucalyptus oil or thimal
- Hog-fat is used for the easing of cough in the traditional popular therapy.
- the great disadvantage of the synthetic medicaments is that they comprise smaller or higher amount of exciting alkaloids, therefore certain compositions are considered as doping (stimulating) agents.
- the alkaloids can also have an undesired side-effect to the heart.
- the drawback of the galenic formulations is that their effect is relatively weak. According to French Patent Specification
- compositions according to the present invention comprise hog-fat, eucalyptus oil and optionally mustard in a weight ratio of 700 to 1200 : : 2.5 to 50 : 70 to 160 as active ingredients.
- composition is not sterilized, it should also comprise an antioxidant.
- the weight ratio of hog-fat to the antioxydant should be 700 to 1200 : : 0.1 to 5.
- compositions according to the invention are assured by hog-fat, eucalyptus oil and mustard, latter being optionally present.
- Mustard is not an essential element of the compositions, however, its addition enhances the activity of the compositions.
- the active ingredient of the hog-fat is mainly prostaglandine but also the volatile fatty acids ( triglycerides) have a favourable effect on the inner cilia of the bronchi.
- the active ingredient of cough-relieving and expectorant effect of mustard is mustard oil.
- the cough-relieving effect of eucalyptus oil is known, but in our case it is also useful for the perfuming of the composition.
- the effect of the compositions of the invention is different from the additive effect of hog-fat, eucalyptus oil and mustard which components all have a very low effect per se, as it is widely known. These components synergistically enhance each-others activity.
- compositions exerts their effect partly transdermally, partly by the route of evaporation inhalation.
- the temperature needed for the latter process is assured by the constant temperature of the human body.
- the composition can be sterilized, but the sufficient chemical and microbiological stability can also be assured by addition of an antioxidant.
- an antioxidant preferably butyl hydroxytoluene, commonly used for protecting hog-fat from growing rancid, can be used.
- the active agents of the invention can be applied onto the skin by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use. They can be applied alone, but are generally applied with a pharmaceutical carrier.
- composition When the composition is formulated as a plaster the active ingredients are preferably absorbed by a suitable carrier, optionally covered by a removable protective layer and the carrier is preferably supplied with means suitable for fixing the carrier onto the skin.
- suitable carrier gauze bandage purified cotton, absorbent gauze, terry cloth or any other hydrophobic, soft, non-irritating material can be mentioned.
- the carrier is preferably impregnated on the back side by e.g. a polymer such as polyvinyl chloride, or such a carrier is used of which the back side is of close texture.
- a suitable insulating material e.g. aluminium or polymer foil onto the back side of the carrier.
- the mixture of the active ingredients can be applied onto the chest of the patient confined to bed per se, or absorbed by a suitable carrier, the carrier is preferably fixed onto the skin of the patient.
- the fixing can be carried out by sticking the carrier saturated by the active ingredients on its two or four edges onto the skin by the aid of adhesive plaster stripes, but the carrier can also be put onto a piece of an adhesive plaster being bigger in size than the carrier itself and the parts of the plaster overlaping the carrier fasten the carrier to the akin.
- the adhesive tape can be of the surgical type with an adhesive being neutral from the point of view of skin allergy.
- the tape can be a rubber based one or can have an acrylate coating attached.
- the adhesive tape can be woven or nonwoven fabric.
- That side of the carrier saturated with the active ingredients which will contact the skin is preferably covered by a protective layer which can be removed before use.
- a protective layer polyvinyl chloride, polyethylene or aluminium foil can preferably be used.
- the active ingredients can also be incorporated into creams, dressings, glycerogelatins, pastes and ointments.
- vaseline or any other carrier commonly used in such types of pharmaceutical formulations can be employed as carrier.
- the plaster according to the invention suitable for external application contains from about 1 g to 100 g of active ingredients per unit.
- the active ingredients will ordinarily be present in an amount of about 5 to 100 % by weight based on the total weight of the compositions.
- the composition according to Figure 1 is prepared by saturating the 1 terry cloth piece with the mixture of the active ingredients in an amount of 250 to 2500 g/m 2 , sticking the 2 polyvinyl chloride or other foil to one of ita aides, placing this side onto the 3 adhesive plaster and covering the other side which will be in contact with the skin with the 4 polyvinyl or polyethylene foil which can be removed before use.
- the preferred form of the preparation according to the invention is a square or rectangle with 10 to 20 cm sides.
- the preparation according to the invention has no side-effect, it is not toxic. It exhibits its effect already within 10 to 15 minutes and this effect is exerted throughout 6 to 8 hours. Thereafter the treatment can be repeated without any harmful consequence. Its application is simple, it can be used disregard to the age of the patient and the section of the day.
- the invention is illustrated by the following, non-limiting examples.
- Example 1 hog-fat 1000 g eucalyptus oil 3 g butyl hydroxytoluene 0.1 g
- terry cloth (10x20 cm) is aaturated with the mixture. That side of the terry cloth which will not contact the skin is of close structure in order to prevent the evaporation of the volatile oil and the penetration of hog-fat.
- the carrier saturated like this is applied onto a 13x13 cm piece of an adhesive plaster and that side of the terry cloth which will contact the skin is covered by a polyvinyl chloride foil,
- Example 2 hog-fat 1200 g eucalyptus oil 43 g butyl hydroxytoluene 3 g mustard 90 g
- the above components are mixed and a
- 20x20 cm piece of gauze is aaturated with the mixture, One side of the gauze is impregnated with polyvinyl chloride and it is fixed onto the cheat of the patient by the aid of two atripes of an adhesive plaster being on the opposite sides of the carrier.
- the above components are mixed, thereafter the mixture is sterilized and cooled.
- a hydrophobic textile (10x15 cm) is saturated with this mixture and a polyvinyl chloride foil of the same size is sticked onto that aide of the material which will not contact the akin.
- the carrier is applied onto a 12 x 17 cm piece of an adhesive plaster, thereafter that part of the carrier, which will contact the akin is covered with a polyethylene foil.
- Example 5 Ointment hog-fat 700 g eucalyptus oil 5 g mustard 70 g butyl hydroxytoluene 5 g vaseline 1000 g
- the ingredients are thoroughly mixed.
- the effect of the composition according to the invention is verified by the following tests: The composition according to Example 2 was applied.
- the composition was applied onto the cheat of 17 patients suffering from asthma or bronchitis. The cough completely ceased in the case of 8 patients, it was relieved in great extent in 5 cases and in less extent in 4 cases. The composition was applied for night. No disadvantageous or harmful side-effect could be observed.
- the composition was applied onto the chest of 4 children suffering from double form of chronic bronchitis. The cough was significantly relieved even due to only one treatment and the stethoscopic diagnosis improved as well in all the four cases, c) The composition was applied onto the chest of 10 patients. The results are summarized in Table 1. Table 1
- composition was applied onto the chest of 10 1 to 4 years old and 10, 5 to 14 years old patients suffering from obstructive bronchitis, asthma bronchiale or bronchopneumonia.
- the composition was applied at night, before going to bed for the younger children, while it was used at night and day too, for the elder children, in both cases as a supplement of the basic medicines.
- the younger children (1 to 4 years old) became aubatantially tranquil, they could better sleep, while they auffered from air-thrist before the application of the composition.
- the effect of the composition decreased after about 2 hours.
- a carrier was saturated with mustard and this waa applied to the chest of the same 6 patients. No effect could be observed in any one of the cases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU823048A HU187414B (en) | 1984-10-12 | 1984-10-12 | Process for producing cough-preparation of physiologically relieving and sedative effect, fixable on skin |
| HU304882 | 1984-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0198003A1 true EP0198003A1 (en) | 1986-10-22 |
Family
ID=10962279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP85905100A Withdrawn EP0198003A1 (en) | 1984-10-12 | 1985-10-11 | Cough-relieving compositions |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0198003A1 (da) |
| DD (1) | DD243642A5 (da) |
| DK (1) | DK277486A (da) |
| HU (1) | HU187414B (da) |
| WO (1) | WO1986002270A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4433191A1 (de) * | 1994-09-17 | 1996-03-21 | Lohmann Therapie Syst Lts | Selbstklebendes Pflaster zur Abgabe von Wirkstoff an die Umgebung eines Trägers |
| RU2125855C1 (ru) * | 1996-10-08 | 1999-02-10 | Открытое акционерное общество Волгоградский маслоэкстракционный завод "Сарепта" | Горчичник |
| IN183330B (da) * | 1998-03-23 | 1999-11-20 | Dalmia Ct For Biotechnology | |
| AU2000250055A1 (en) * | 2000-04-13 | 2001-10-30 | Lectec Corporation | Therapeutic patch containing a liquid or gel organic compound as a carrier |
| US20040071757A1 (en) * | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
| CN104971322A (zh) * | 2015-06-11 | 2015-10-14 | 钟兴欢 | 一种黄皮清咽润喉片 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB190719133A (en) * | 1907-08-26 | 1908-05-07 | William Bryant | An Improved Ointment |
| AT261811B (de) * | 1963-11-18 | 1968-05-10 | Sophie Lintner | Verfahren zur Herstellung einer homogenen Salbe |
-
1984
- 1984-10-12 HU HU823048A patent/HU187414B/hu not_active IP Right Cessation
-
1985
- 1985-10-11 DD DD85281661A patent/DD243642A5/de not_active IP Right Cessation
- 1985-10-11 EP EP85905100A patent/EP0198003A1/en not_active Withdrawn
- 1985-10-11 WO PCT/HU1985/000060 patent/WO1986002270A1/en not_active Ceased
-
1986
- 1986-06-12 DK DK277486A patent/DK277486A/da not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8602270A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1986002270A1 (en) | 1986-04-24 |
| HU187414B (en) | 1986-01-28 |
| DD243642A5 (de) | 1987-03-11 |
| DK277486D0 (da) | 1986-06-12 |
| DK277486A (da) | 1986-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5601838A (en) | Method for treating pain associated with herpes-zoster and post-herpetic neuralgia | |
| US5976547A (en) | Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery | |
| AU2001245449B2 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
| KR0143916B1 (ko) | 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 | |
| US5332577A (en) | Transdermal administration to humans and animals | |
| US5612382A (en) | Composition for percutaneous absorption of pharmaceutically active ingredients | |
| AU2001245449A1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
| WO2006017632A1 (en) | An analgesic patch for sports injury and rehabilitation medicine and method to alleviate pain | |
| JP4596751B2 (ja) | 消炎鎮痛貼付剤 | |
| EP0198003A1 (en) | Cough-relieving compositions | |
| NZ238512A (en) | Transdermal compositions containing a fatty acid ester or a paraffin | |
| JP4041162B2 (ja) | ルビジウムイオンを用いる製剤 | |
| TW305761B (da) | ||
| US4994445A (en) | Substances with therapeutic applications comprising organo-silicon compounds | |
| BETTMAN | A simpler technic for promoting epithelization and protecting skin grafts | |
| EP0002003B1 (en) | Medical and cosmetic compositions containing a thixotropic aluminium derivative; process for producing them | |
| EP0260645A1 (de) | Therapeutisches System zur lokalen Applikation von Pharmawirkstoffen | |
| JPS60163811A (ja) | プロプラノロ−ル含有外用貼付剤 | |
| US3098790A (en) | Admixture of aluminum metal powder and powdered vegetable gum for treatment of open wounds | |
| JPH10265405A (ja) | インスリン含有の皮膚外用製剤 | |
| Price | How essential oils enter the body | |
| JP2002080386A (ja) | 貼着用テーピング材 | |
| JP3036689U (ja) | 蓐瘡等の治療用貼付材 | |
| CA1339073C (en) | Penetration enhancement with binary system of cell envelope disordering compounds & lower alcohols | |
| Stenström et al. | Leprosy wound healing with ordinary adhesive tape: a preliminary report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL |
|
| 17P | Request for examination filed |
Effective date: 19861002 |
|
| 17Q | First examination report despatched |
Effective date: 19890120 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19900221 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LEOPOLD, GASPAR Inventor name: SZIKLAI, ATTILA |